Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
Valerie Vanhooren, PhD, Co-Founder and Chief Executive Officer at Ona Therapeutics, said: “The oversubscribed Series B marks an important step to advancing ONA‑255 toward clinical proof of concept in breast cancer, while progressing early clinical development activities for ONA‑389 in colorectal cancer. We are proud to have assembled a high-quality syndicate of investors who share our conviction in the differentiated science behind Ona’s novel targets and their potential to address drug resistance. Supported by a highly experienced and talented team, this financing strengthens our commitment to tackling hard-to-treat cancers through meaningful innovation and addressing the significant unmet need faced by patients with limited treatment options.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data